- Home
- ECBK vs ANVS Comparison
ECBK vs ANVS Comparison
Compare ECBK & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECBK | ANVS |
|---|---|---|
| Founded | 1919 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.5M | 76.6M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ECBK | ANVS |
|---|---|---|
| Price | $20.32 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 5.5K | ★ 997.8K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.83 | 39.39 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $598,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.78 | ★ N/A |
| Revenue Growth | ★ 3.64 | N/A |
| 52 Week Low | $14.83 | $1.22 |
| 52 Week High | $21.51 | $5.50 |
Technical Indicators
Market Signals| Indicator | ECBK | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 45.72 | 22.48 |
| Support Level | $20.03 | N/A |
| Resistance Level | $20.79 | $2.02 |
| Average True Range (ATR) | 0.45 | 0.10 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 8.46 | 3.65 |
Price Performance
Historical ComparisonAbout ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.